Nguyen C, et al. (2007) Differential regulation of the Cdk5-dependent phosphorylation sites of inhibitor-1 and DARPP-32 by depolarization. J Neurochem 103, 1582-93 17868322

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T75-p - DARPP-32 (mouse) ▲

Modsite: RPNPCAYtPPSLKAV SwissProt Entrez-Gene Orthologous residues DARPP‑32 (human): T75‑p, DARPP‑32 iso2 (human): T39‑p, DARPP‑32 (mouse): T75‑p, DARPP‑32 (rat): T75‑p, DARPP‑32 (cow): T75‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Species studied:  mouse Comments:  C57BL/6 mice acute dorsal striatal slices Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CDK5 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes depolarization decrease NMDA decrease okadaic_acid increase calyculin_A increase NMDA calyculin_A inhibit treatment-induced increase NMDA okadaic_acid inhibit treatment-induced increase AMPA decrease kainic_acid decrease APV NMDA inhibit treatment-induced decrease MK801 AMPA no effect upon treatment-induced decrease APV AMPA no effect upon treatment-induced decrease APV depolarization no effect upon treatment-induced decrease Ni(2+) increase Ni(2+) NMDA inhibit treatment-induced decrease nimodipine NMDA no effect upon treatment-induced decrease Ni(2+) NMDA no effect upon treatment-induced decrease 100 micro molar/litre concentration EGTA increase NMDA EGTA inhibit treatment-induced increase

S6-p - PPP1R1A (mouse) ▲

Modsite: __MEPDNsPRKIQFT SwissProt Entrez-Gene Orthologous residues PPP1R1A (human): S6‑p, PPP1R1A (mouse): S6‑p, PPP1R1A (rat): S6‑p, PPP1R1A (rabbit): S6‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Species studied:  mouse Comments:  C57BL/6 mice acute dorsal striatal slices Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CDK5 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes depolarization decrease NMDA decrease okadaic_acid increase calyculin_A increase NMDA calyculin_A inhibit treatment-induced increase NMDA okadaic_acid inhibit treatment-induced increase AMPA decrease kainic_acid decrease APV NMDA inhibit treatment-induced decrease MK801 AMPA no effect upon treatment-induced decrease APV AMPA no effect upon treatment-induced decrease APV depolarization no effect upon treatment-induced decrease Ni(2+) increase Ni(2+) NMDA inhibit treatment-induced decrease nimodipine NMDA no effect upon treatment-induced decrease Ni(2+) NMDA no effect upon treatment-induced decrease 100 micro molar/litre concentration EGTA increase NMDA EGTA inhibit treatment-induced increase

S67-p - PPP1R1A (mouse) ▲

Modsite: LKSTLsMsPRQRKKM SwissProt Entrez-Gene Orthologous residues PPP1R1A (human): S67‑p, PPP1R1A (mouse): S67‑p, PPP1R1A (rat): S67‑p, PPP1R1A (rabbit): S67‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Species studied:  mouse Comments:  C57BL/6 mice acute dorsal striatal slices Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CDK5 (human) pharmacological inhibitor of upstream enzyme PHOSPHATASE PPP2CA (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes depolarization decrease NMDA decrease okadaic_acid increase calyculin_A increase NMDA calyculin_A inhibit treatment-induced increase NMDA okadaic_acid inhibit treatment-induced increase AMPA decrease kainic_acid decrease APV NMDA inhibit treatment-induced decrease MK801 AMPA no effect upon treatment-induced decrease APV AMPA no effect upon treatment-induced decrease APV depolarization no effect upon treatment-induced decrease Ni(2+) increase Ni(2+) NMDA inhibit treatment-induced decrease nimodipine NMDA no effect upon treatment-induced decrease Ni(2+) NMDA no effect upon treatment-induced decrease 100 micro molar/litre concentration EGTA increase NMDA EGTA inhibit treatment-induced increase